# Holmusk USA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/holmusk-usa

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.holmusk.com
- Total disclosed funding: $80M
- Latest round: Series B (Jan 9, 2023)
- Investors on record: 9

## About

Holmusk USA, Inc. is a data-driven company specializing in behavioral health solutions, providing critical insights through its advanced NeuroBlu platform to enhance patient outcomes and healthcare interventions.Holmusk USA, Inc., founded in 2015, is headquartered in New York, US. The company focuses on behavioral health analytics, utilizing their flagship NeuroBlu Database to support clinical research. Led by CEO Nawal Roy, Holmusk has concluded 7 deals, with the latest funding round occurring in October 2023 where they raised USD 30 mn from Allscripts Healthcare, LLC, bringing their total amount raised to USD 30 mn.Holmusk offers data-driven solutions primarily through its NeuroBlu Database and NeuroBlu Analytics, which comprise a repository of clinical data for over 1 million patients. These tools empower healthcare researchers and providers to perform detailed analyses on various behavioral health conditions, including substance use disorders, major depressive disorder, and bipolar disorder. Their services, incorporating advanced natural language processing, cater to academic institutions, healthcare providers, payers, and life sciences companies, enhancing research capabilities and patient outcomes.In 2018, Holmusk reported revenue of USD 1,099,221.50 with an EBITDA of USD -3,367,319.10. Their revenue model is based on subscription agreements and partnerships that grant access to the NeuroBlu platform for clinical research and care management applications.On October 2, 2023, Holmusk USA, Inc. raised USD 30 mn in venture funding, which will be utilized to expand the growth of its NeuroBlu Database product. The company aims to enhance its offerings and possibly explore new market expansions, although specific geographic targets have not been disclosed.

## Funding rounds

- Series B, Jan 9, 2023, $46M — Allscripts Healthcare, LLC, dRx Capital, Health Catalyst Capital Management, Northwell Holdings, Octave Capital
- Series A, Apr 6, 2021, $26M — Health Catalyst Capital Management, Optum Ventures, Octave Capital
- Series A, Sep 24, 2018, $5.6M — Alchemy Investment Management Pte Ltd, Octave Capital, Capikris Foundation
- Seed, Nov 2, 2016, $2.3M — Alchemy Investment Management Pte Ltd, Maddog Ventures

## Investors

- Alchemy Investment Management Pte Ltd — Seed, Series A
- Maddog Ventures (https://capitalatlas.ai/funds/maddog-ventures) — Seed
- Octave Capital (https://capitalatlas.ai/funds/octave-capital) — Series A, Series B
- Capikris Foundation — Series A
- Health Catalyst Capital Management (https://capitalatlas.ai/funds/health-catalyst-capital-management) — Series A, Series B
- Optum Ventures (https://capitalatlas.ai/funds/optum-ventures) — Series A
- Allscripts Healthcare, LLC — Series B
- dRx Capital (https://capitalatlas.ai/funds/drx-capital) — Series B
- Northwell Holdings (https://capitalatlas.ai/funds/northwell-holdings) — Series B